circulating tumor dna (ctdna) is the cell-free dna in body fluid, such as serum, plasma, cerebrospinal fluid and synovial fluid. in the formation and development stages of the primary tumor, the tumor cell will die and wither and their dna will be freed into the blood. the ctdna in the peripheral blood of the tumor patients has a higher content than the healthy individuals. besides, the ctdna is called cell-free ctdna.
ubiopsy using next generation sequencing technology, can partly replace the traditional histology invasive biopsy. by analyzing ctdna with ngs, early detection of tumor, personalized treatment decision and supervision of prognosis can be monitored.
advanced：the illumina high-throughput sequencing system and bioinformatics analysis platform are adopted.
noninvasive：in ctdna noninvasive personalized tumor treatment genetic test, such as invasive test means as needle biopsy and operations are unnecessary.
sensitive：compared with traditional tumor markers, ctdna can truthfully reflect the progress of tumor as it is of high sensitivity.
professional：the interpretation of the test is based upon our powerful database including both the authoritative databases and the latest clinical research results.
